WIP Counting

Wall Street is complicit in WIP Counting+ (Work-In-Process Counting) at least in the pharmaceutical industry.

Scandal headline on Wall Street after the move to stop counting R&D WIP 

Exhibit 1: Illustrative headline of how difficult it will be to change the fundamental measure of progress in R&D, even though it is commonly acknowledged to be a flawed measure. Individuals will spend inordinate amounts of time trying to translate new measures into the old in order to draw comparisons.